Floatz logo

AMISULPRIDE

Chronic Pain, Widespread

susanne beckerSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Chronic Pain, Widespread cohort.

Asset / SponsorPhaseRating
Duloxetine
Cukurova University
Phase 4BBB
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4BB
PIPERAZINE, 1-(BIS(4-FLUOROPHENYL)METHYL)-4-(3-PHENYL-2-PROPENYL)-, (E)-
Taipei Veterans General Hospital, Taiwan
Phase 4BB
LIDOCAINE
Peking University Third Hospital
Phase 2BB
ds-5565
Daiichi Sankyo
Phase 3B

View all 36 →

Same molecule, other indications

AMISULPRIDE is also rated in:

schizophreniaDormant
BB
Indicative ·
71 / 100
View asset →
psychotic disorderDormant
BB
Indicative ·
71 / 100
View asset →
schizophreniform disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →